<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958711</url>
  </required_header>
  <id_info>
    <org_study_id>U-0801</org_study_id>
    <nct_id>NCT00958711</nct_id>
  </id_info>
  <brief_title>The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer</brief_title>
  <official_title>The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synovis Surgical Innovations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and
      compare its performance with the standard of care, saline moistened gauze, for the treatment
      of diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Budgetary
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Not Healed by Number of Days After Procedure</measure>
    <time_frame>Day 20, Day 40, Day 60, Day 80</time_frame>
    <description>Time to complete healing was captured by Kaplan-Meier Plot showing percentage of participants not healed by number of days after procedure. Patients were considered healed at their first follow-up visit where the patient's would had healed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Wounds Healed at 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Healing Pathway Markers</measure>
    <time_frame>Day 0, 72 hours post-procedure, Week 1, Week 2, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial Burden</measure>
    <time_frame>Day 0, Week 1 - Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Mean of Original Wound Size From Baseline by Week</measure>
    <time_frame>Day 0, Week 4, Week 8, Week 12</time_frame>
    <description>The percent of original wound size was calculated using the following formula: measure at baseline minus measure at follow-up visit divided by measure at baseline. In cases when the baseline depth was reported as 0cm, the minimum non-zero value in the sample (0.1cm) was imputed so a percent reduction measure could be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ulcer Recurrence</measure>
    <time_frame>Week 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Device-related Adverse Events (AE)</measure>
    <time_frame>Week 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Procedure-related Adverse Events (AE)</measure>
    <time_frame>Week 1 to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Device Failures</measure>
    <time_frame>Week 1 to Week 24</time_frame>
    <description>Includes failure to heal the ulcer by the 12-week visit under the Intent-to-Treat principle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Device Removals</measure>
    <time_frame>Week 1 to Week 24</time_frame>
    <description>Device removal is included in device failure under ITT. Subjects who experienced procedure-related events were also device failures under ITT. This endpoint is equivalent to device failure rates reported above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Dressing Use</measure>
    <time_frame>Week 1 to Week 12</time_frame>
    <description>Ease of usage on a 5-point scale where 1=greatest ease of use and 5=greatest difficult</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Biologic - Unite Biomatrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline and Gauze</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unite Biomatrix</intervention_name>
    <description>Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
    <arm_group_label>Biologic - Unite Biomatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline and Gauze</intervention_name>
    <description>gauze moistened with sterile saline</description>
    <arm_group_label>Saline and Gauze</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A full thickness diabetic foot ulcer with a viable wound bed free of necrotic material
             (grade 1 on Wagner scale).

          2. Diagnosis of diabetes mellitus (type I or II) adequately controlled.

          3. The ulcer is greater than 4 weeks duration.

          4. Three or fewer ulcers separated by &gt; 3.0 cm distance.

          5. Post-debridement, the ulcer size must be between 1 and 10 sq cm2.

          6. Ankle/brachial index is between 0.7 to 1.2 and or one of the following must be
             present:

               -  transcutaneous partial pressure oxygen (TcPO2) &gt; 30 mmHg at the ankle

               -  toe pressure of &gt;40mm Hg or a Doppler waveform consistent with adequate flow in
                  the foot (biphasic or triphasic)

          7. At least 18 years old.

          8. Able and willing to provide a voluntary written informed consent.

          9. Able and willing to wear an off-loading orthopedic shoe.

         10. Able and willing to attend scheduled follow-up visits and study related exams.

        Exclusion Criteria:

          1. Greater than 30% reduction in wound size during first week of observation by the
             investigator.

          2. Ulcer with exposed tendon or bone.

          3. Gross clinical infection at the study ulcer site including cellulitis and
             osteomyelitis.

          4. Gangrene.

          5. Active Charcot's disease as determined by clinical and radiographic examination.

          6. Ulcer of a non-diabetic pathophysiology (e.g., rheumatoid, radiation-related, and
             vasculitis related ulcers).

          7. Known severe anemia.

          8. Known serum albumin &lt; 2.5.

          9. Renal failure with Creatinine &gt; 2.5.

         10. Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell
             disease, HIV.

         11. Severe liver disease as defined by the treating physician or patient's primary care
             physician.

         12. Malignancy at or near the ulcer site.

         13. Any condition judged by the investigator that would cause the study to be detrimental
             to the patient.

         14. Presence of a hematology, clinical, chemistry or other test obtained within 7 days of
             screening that is outside the normal range for the laboratory and is determined to be
             clinically significant by the investigator.

         15. Received another investigational device or drug within 30 days of Day 0.

         16. Radiation therapy, chemotherapy or immunosuppressive therapy within 30 days of
             enrollment.

         17. Received another allograft, autograft or xenograft within 30 days of the Day 0.

         18. Known allergy to equine derived tissue.

         19. Alcohol or drug abuse, defined as current medical treatment for substance abuse.

         20. Pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiyan Diabetes Center</name>
      <address>
        <city>Evans</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot &amp; Ankle Associates of Central Illinois, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Foot and Ankle</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle East</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina East Family Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Foot &amp; Ankle Physicians</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Wound Care Thoracic &amp; Vascular Associates of Kinston P.A.</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Foot &amp; Ankle Associates of North Carolina, PLLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>September 3, 2019</results_first_submitted>
  <results_first_submitted_qc>December 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Biologic - Unite Biomatrix</title>
          <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
        </group>
        <group group_id="P2">
          <title>Saline and Gauze</title>
          <description>Saline and Gauze: gauze moistened with sterile saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Biologic - Unite Biomatrix</title>
          <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
        </group>
        <group group_id="B2">
          <title>Saline and Gauze</title>
          <description>Saline and Gauze: gauze moistened with sterile saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="10.7"/>
                    <measurement group_id="B2" value="54.9" spread="10.2"/>
                    <measurement group_id="B3" value="56.39" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Not Healed by Number of Days After Procedure</title>
        <description>Time to complete healing was captured by Kaplan-Meier Plot showing percentage of participants not healed by number of days after procedure. Patients were considered healed at their first follow-up visit where the patient's would had healed.</description>
        <time_frame>Day 20, Day 40, Day 60, Day 80</time_frame>
        <population>Intent-to-Treat (ITT): all randomized participants who provided consent..</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Not Healed by Number of Days After Procedure</title>
          <description>Time to complete healing was captured by Kaplan-Meier Plot showing percentage of participants not healed by number of days after procedure. Patients were considered healed at their first follow-up visit where the patient's would had healed.</description>
          <population>Intent-to-Treat (ITT): all randomized participants who provided consent..</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91"/>
                    <measurement group_id="O2" value="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                    <measurement group_id="O2" value="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61"/>
                    <measurement group_id="O2" value="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Wounds Healed at 12 Weeks</title>
        <time_frame>Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Wounds Healed at 12 Weeks</title>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Healed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Healed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wound Healing Pathway Markers</title>
        <time_frame>Day 0, 72 hours post-procedure, Week 1, Week 2, Week 4</time_frame>
        <population>Source document notes &quot;no data provided.&quot; Limited information available since product no longer licensed with Baxter.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Healing Pathway Markers</title>
          <population>Source document notes &quot;no data provided.&quot; Limited information available since product no longer licensed with Baxter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Burden</title>
        <time_frame>Day 0, Week 1 - Week 12</time_frame>
        <population>Source document notes &quot;no data provided.&quot; Limited information available since product no longer licensed with Baxter.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Burden</title>
          <population>Source document notes &quot;no data provided.&quot; Limited information available since product no longer licensed with Baxter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Mean of Original Wound Size From Baseline by Week</title>
        <description>The percent of original wound size was calculated using the following formula: measure at baseline minus measure at follow-up visit divided by measure at baseline. In cases when the baseline depth was reported as 0cm, the minimum non-zero value in the sample (0.1cm) was imputed so a percent reduction measure could be calculated.</description>
        <time_frame>Day 0, Week 4, Week 8, Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Mean of Original Wound Size From Baseline by Week</title>
          <description>The percent of original wound size was calculated using the following formula: measure at baseline minus measure at follow-up visit divided by measure at baseline. In cases when the baseline depth was reported as 0cm, the minimum non-zero value in the sample (0.1cm) was imputed so a percent reduction measure could be calculated.</description>
          <population>ITT</population>
          <units>Percentage mean of wound size</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Length</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.879" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.754" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Width</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.809" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.750" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Depth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.820" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="1.082" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Area</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.807" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.732" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Length</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.705" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.695" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Width</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.650" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.671" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Depth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.612" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="1.365" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Area</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.546" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.592" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Length</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.381" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.567" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Width</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.323" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.465" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Depth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.304" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="1.347" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Area</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.341" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                    <measurement group_id="O2" value="0.433" spread="NA">Study sponsored by other company, and only abbreviated results available without this data point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ulcer Recurrence</title>
        <time_frame>Week 1 to Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ulcer Recurrence</title>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Device-related Adverse Events (AE)</title>
        <time_frame>Week 1 to Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Device-related Adverse Events (AE)</title>
          <population>ITT</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Procedure-related Adverse Events (AE)</title>
        <time_frame>Week 1 to Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Procedure-related Adverse Events (AE)</title>
          <population>ITT</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Device Failures</title>
        <description>Includes failure to heal the ulcer by the 12-week visit under the Intent-to-Treat principle.</description>
        <time_frame>Week 1 to Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Device Failures</title>
          <description>Includes failure to heal the ulcer by the 12-week visit under the Intent-to-Treat principle.</description>
          <population>ITT</population>
          <units>Devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Device Removals</title>
        <description>Device removal is included in device failure under ITT. Subjects who experienced procedure-related events were also device failures under ITT. This endpoint is equivalent to device failure rates reported above.</description>
        <time_frame>Week 1 to Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Device Removals</title>
          <description>Device removal is included in device failure under ITT. Subjects who experienced procedure-related events were also device failures under ITT. This endpoint is equivalent to device failure rates reported above.</description>
          <population>ITT</population>
          <units>Devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Dressing Use</title>
        <description>Ease of usage on a 5-point scale where 1=greatest ease of use and 5=greatest difficult</description>
        <time_frame>Week 1 to Week 12</time_frame>
        <population>ITT. Note: Limited information available since product no longer licensed with Baxter. The only stats analysis information available provides data for Unite Biomatrix treatment arm, and will need to assume analysis was not performed for control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic - Unite Biomatrix</title>
            <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
          </group>
          <group group_id="O2">
            <title>Saline and Gauze</title>
            <description>Saline and Gauze: gauze moistened with sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Dressing Use</title>
          <description>Ease of usage on a 5-point scale where 1=greatest ease of use and 5=greatest difficult</description>
          <population>ITT. Note: Limited information available since product no longer licensed with Baxter. The only stats analysis information available provides data for Unite Biomatrix treatment arm, and will need to assume analysis was not performed for control arm.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ease of Preparation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Handling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfortability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Securability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day -12 through Day 180</time_frame>
      <desc>Source vocabulary unknown.</desc>
      <group_list>
        <group group_id="E1">
          <title>Biologic - Unite Biomatrix</title>
          <description>Unite Biomatrix: Collagen based, decellularized equine pericardial dressing for skin surface wounds</description>
        </group>
        <group group_id="E2">
          <title>Saline and Gauze</title>
          <description>Saline and Gauze: gauze moistened with sterile saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of death unknown, arbitrarily selected body system of 'Investigations'</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study initially sponsored by Synovis Surgical Innovation, and product now licensed with Biomed Design. Unable to obtain all data for study. Clinical Study Report not located and results summarized from an abbreviated Statistical Analysis Report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Baxter Clinical Trials Disclosure Call Center</name_or_title>
      <organization>Baxter Healthcare</organization>
      <phone>(224) 948-7359</phone>
      <email>Global_CORP_ClinicalTrialsDisclosure@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

